At a glance
ClinicalIndex Comparison RecordN/ACompleted· 458 enrolled
Drug / intervention
Firehawk +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Multi-center Randomized Trial Assessing the Safety and Effectiveness of Biodegradable Polymer Target Release Rapamycin-Eluting STent vs. XIENCE V Everolimus-Eluting Stent for the Treatment of Coronary Artery Disease
In Brief
A clinical study evaluating Firehawk and Xience V for Coronary Artery Disease. Completed, enrolled 458 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate new generation drug eluting stent (DES) of MicroPort of its safety, efficacy and delivery system in treating CAD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedSep 2010
Primary CompletionMay 2012
Study CompletionDec 2016
TodayJul 2026
First PostedSep 8, 2010
Enrollment StartSep 1, 2010
Primary CompletionMay 1, 2012
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 15.8 years ago
Interventions
Firehawkdevice
Implantation of Firehawk drug eluting stent
Xience Vdevice
Implantation of Xience V drug eluting stent